Financial/Stock Related
EECP® Therapy
Q: What is your stock symbol?
A: Vasomedical is traded on the Over the Counter Bulletin Board (OTCBB) under the symbol VASO.OB.
Q: Who is Vasomedical’s transfer agent?
A: Our transfer agent is American Stock Transfer & Trust Company.
Q: Does Vasomedical issue dividends?
A: No.
Q: Does Vasomedical provide a direct stock purchase plan?
A: No.
Q: Who are Vasomedical's auditors?
A: Our independent registered public accounting firm is Rothstein Kass.
Q: What is Vasomedical’s fiscal year?
A: Our fiscal year starts June 1 and ends May 31.
Q: When will the Company’s next press release be issued?
A: We do not disclose future press release dates.
Q: What is your Investor Relations policy?
A: We comply with SEC regulations requiring a full and fair public disclosure of information relevant to the performance of the Company.
Q: Does Vasomedical comment on stock activity?
A: No. It is our policy not to comment on trading activity or stock price.
Q: What percentage of shares outstanding does management hold?
A: Management holds about 9% of Vasomedical shares on a fully-diluted basis.
Q: How do I obtain investor relations materials?
A: In addition to accessing information on this website, investors may also request an Investor Kit which contains recent press releases and financial filings, current annual report, and clinical and company information by sending an email to customerservice@vasomedical.com or by calling 1-800-455-3327 ext. 790.
EECP® Therapy
Q: What is EECP® therapy?
A: EECP® therapy is an outpatient treatment for angina and heart failure. The therapy is typically given in 35 one-hour-sessions, five days a week, for seven weeks. Patients lie down on a padded table and have their calves and lower and upper thighs wrapped in blood pressure-like cuffs. The system, which is synchronized to the individual patient’s cardiac cycle, inflates the cuffs with air to create external pressure when the heart is resting (diastole) and deflates the cuffs just before the heart beats (systole). The system’s action, which pulses counter to the heart's beating, increases blood flow to the heart muscle, decreases the heart’s workload and creates a greater oxygen supply for the heart muscle while lowering the heart's need for oxygen.
Q: What are the labeled indications for use of EECP therapy?
A: Vasomedical EECP therapy systems are intended for use in the treatment of patients with stable or unstable angina, congestive heart failure, acute myocardial infarction, or cardiogenic shock.
Q: What are the advantages of EECP therapy over alternative therapies for refractive angina?
A: EECP therapy is a safe, highly beneficial, non-invasive outpatient treatment that is believed to create new pathways around blocked arteries in the heart by expanding networks of tiny blood vessels that help increase blood flow to the heart muscle. EECP treatment can reduce or eliminate the frequency and intensity of chest pain, decrease the need for medication and greatly improve the ability to participate in activities of daily living. After receiving EECP treatment, patients often are able to enjoy moderate exercise.
More invasive options including angioplasty and coronary stent placements, as well as coronary artery bypass grafting (CABG) sometimes fail, pose risks and are expensive. There are many factors that increase the risk of these invasive procedures, including:
- Age
- The existence of comorbid conditions, such as diabetes or renal insufficiency
- Small blood vessels frequently seen in women
- Coronary anatomy that is not suited to surgical intervention
- Prior failed interventional procedures
- Previous CABG
Q: What is the Medicare reimbursement policy for EECP therapy?
A: CMS established a national Medicare reimbursement policy for EECP therapy in the treatment of patients with angina and angina-like symptoms in 1999. Extensive third-party coverage policies have been established on an individual basis similar to that of CMS. For additional information on reimbursement, please click here www.eecp.com.
Q: In which peer-reviewed / clinical journals have articles or abstracts on EECP therapy been published?
A: Data on EECP therapy has been widely published. To view a complete list of articles about EECP therapy that have been published in peer-reviewed journals and abstracts presented at major conferences please visit the EECP Therapy Bibliography.
Q: Can Vasomedical’s EECP therapy systems be legally marketed in the USA and elsewhere?
A: Vasomedical EECP therapy systems may be legally marketed in the USA, Canada, the European Union, and several other countries for use in the treatment of patients with stable or unstable angina, congestive heart failure, acute myocardial infarction, or cardiogenic shock. Information regarding a specific country may be obtained by contacting Vasomedical.
Q: Do you own any patents covering EECP therapy?
A: Yes. We own seven U.S. patents that expire between 2006 and 2021. In addition, more than 20 foreign patents have been issued that expire at various times from 2007 to 2022. There are four major patent applications pending relative to aspects of the newer EECP systems, potential improvements and new methods of treatment.
Q: Do you own any trademarks covering EECP therapy?
A: Yes. We have registered the names "EECP" and "Natural Bypass" as trademarks. The image of the Vasomedical Man is also trademarked.
